Annexon (ANNX) Total Liabilities (2019 - 2026)
Annexon (ANNX) posted quarterly Total Liabilities of $58.4 million for Q1 2026, down 1.49% year-over-year from $59.2 million in Q1 2025, and down 11.48% quarter-over-quarter from $65.9 million in Q4 2025.
Annexon (ANNX) Total Liabilities (2019 - 2026) Analysis & Trends
Annexon's Total Liabilities history runs 8 years deep, the most recent figure standing at $58.4 million for Q1 2026.
- In Q1 2026, Total Liabilities fell 1.49% year-over-year to $58.4 million; the TTM figure through Mar 2026 stood at $58.4 million (down 1.49% YoY), while the FY2025 annual figure was $65.9 million, up 15.72% from the prior year.
- Total Liabilities for Q1 2026 stood at $58.4 million, down from $65.9 million in the prior quarter.
- The five-year high for Total Liabilities was $67.7 million in Q3 2025, with the low at $41.7 million in Q1 2024.
- The 5-year median for Total Liabilities is $52.7 million (2022), against an average of $53.7 million.
- The sharpest annual moves came in 2022 and 2024: Total Liabilities surged 329.13% in 2022, then dropped 22.73% in 2024.
- Annexon's Total Liabilities stood at $53.9 million in 2022, then slipped by 12.59% to $47.1 million in 2023, then increased by 20.9% to $57.0 million in 2024, then increased by 15.72% to $65.9 million in 2025, then slipped by 11.48% to $58.4 million in 2026.
- Business Quant data shows ANNX's Total Liabilities at $58.4 million in Q1 2026, $65.9 million in Q4 2025, and $67.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.62 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.72 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 4.00 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7.02 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 10.03 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.35 Bn |
| 10 | Annexon | 1.00 Bn | 1.00 Bn | - | 60.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 60.01 Mn |
| Mar 31, 2026 | 58.36 Mn |
| Dec 31, 2025 | 65.92 Mn |
| Sep 30, 2025 | 67.70 Mn |
| Jun 30, 2025 | 65.56 Mn |
| Mar 31, 2025 | 59.24 Mn |
| Dec 31, 2024 | 56.97 Mn |
| Sep 30, 2024 | 47.22 Mn |
| Jun 30, 2024 | 45.01 Mn |
| Mar 31, 2024 | 41.66 Mn |
| Dec 31, 2023 | 47.12 Mn |
| Sep 30, 2023 | 46.98 Mn |
| Jun 30, 2023 | 48.29 Mn |
| Mar 31, 2023 | 53.92 Mn |
| Dec 31, 2022 | 53.90 Mn |
| Sep 30, 2022 | 52.12 Mn |
| Jun 30, 2022 | 52.66 Mn |
| Mar 31, 2022 | 49.96 Mn |
| Dec 31, 2021 | 55.13 Mn |
| Sep 30, 2021 | 45.68 Mn |